Clinical and Experimental Ophthalmology · 2012 · 38 citations · 24 references
MedicineOphthalmologySurgeryOcular OncologyOcular PharmacologyOphthalmic SurgeryConjunctival DiseaseConjunctival SurgeryGlaucomaGlaucoma SurgerySubconjunctival Drug DeliveryVitreoretinal SurgeryAntimetabolite CombinationsBleb MorphologyIntraocular Pressure ReductionOutcome MeasuresPostoperative Visual AcuityPrimary Outcome AnalysisSubconjunctival InjectionSurgical Outcomes In Glaucoma
BACKGROUND: To determine whether postoperative subconjunctival bevacizumab significantly alters bleb vascularity. DESIGN: A randomized, prospective interventional study. PARTICIPANTS: Forty-three eyes from 39 patients were recruited, with 21 eyes randomized to subconjunctival injections of 5-fluorouracil, and 22 eyes to combined 5-fluorouracil/bevacizumab. METHODS: All patients who underwent uncomplicated primary antimetabolite augmented trabeculectomy who subsequently required postoperative subconjunctival 5-fluorouracil injection within 4 weeks of surgery were eligible. Patients were randomized to receive subconjunctival 5-fluorouracil only (7.5 mg/0.15 mL) or 5-fluorouracil plus bevacizumab (1.25 mg/0.05 mL). MAIN OUTCOME MEASURES: Primary outcome was bleb vascularity with secondary endpoints including visual acuity, intraocular pressure, bleb morphology, complications and total numbers of 5-fluorouracil injections were recorded at baseline, week 12 and 18 months. RESULTS: At week 12, there was no significant difference between groups for visual acuity, intraocular pressure, bleb vascularity and morphology, or total number of 5-fluorouracil injections. By 18 months, 47.4% of the 5-fluorouracil/bevacizumab group exhibited central bleb avascularity compared with 21.1% of the 5-fluorouracil group (Fisher's exact test, P = 0.17). Two bleb complications (one blebitis; one suture abscess) recorded in the 5-fluorouracil/bevacizumab group. CONCLUSIONS: After a single combined injection, a trend for increased central bleb avascularity was observed, although this effect was not sufficient to reach statistical significance. This, in addition to the occurrence of two bleb-related complications in the bevacizumab group, suggests the need for a larger clinical trial to further evaluate the safety and efficacy of bevacizumab as a modulating agent in glaucoma filtration surgery.
24
A Pilot Study of a System for Grading of Drainage Blebs after Glaucoma Surgery
Anthony P. Wells, Jonathan G. Crowston, J.R. Marks et al. · Journal of Glaucoma · 2004 · 181 citations
Medicine, Ophthalmology, Surgery +17